MINERALYS THERAPEUTICS INC (MLYS)
Sector: Health Care
2026 Annual Meeting Analysis
MINERALYS THERAPEUTICS INC · Meeting: May 21, 2026
Directors FOR
3
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Three Class III Directors for a Three-Year Term Expiring at the 2029 Annual Meeting of Stockholders
Dr. Akkaraju has served since February 2021 and brings deep biotech venture capital and scientific expertise; the company's 3-year stock return of +81.3% outpaces the XBI (SPDR S&P Biotech ETF) by +9.2 percentage points, well below the 65-point threshold needed to trigger an against vote, and no overboarding, attendance, or independence concerns were identified.
Dr. Slingsby is the company's founder and has served since May 2019, bringing extensive biopharmaceutical entrepreneurship and venture capital experience; the company's 3-year stock return of +81.3% outpaces the XBI (SPDR S&P Biotech ETF) by +9.2 percentage points, far below the 65-point threshold needed to trigger an against vote, and no overboarding, attendance, or independence concerns were identified.
Ms. Karydas has served since September 2023 — fewer than 24 months at the time of the meeting — which exempts her from the stock performance trigger under policy; she also brings strong financial and biopharmaceutical executive experience and serves as the audit committee chair and financial expert, satisfying all independence and qualification criteria.
All three Class III nominees pass policy screens: the company's 3-year total shareholder return of +81.3% outperforms the XBI (SPDR S&P Biotech ETF) by +9.2 percentage points, which is far below the 65-point underperformance threshold required to trigger an against vote for a company with strong positive absolute returns. No overboarding, attendance failures, independence issues, or familial relationship concerns were identified for any nominee.
Say on Pay
✓ FORCEO
Jon Congleton
Total Comp
$5,544,727
Prior Support
N/A
Mineralys is an emerging growth company and is not required to hold a Say on Pay vote; however, based on the compensation data disclosed in the proxy, the CEO's total compensation of approximately $5.5 million consists primarily of stock options (variable, performance-linked equity) plus a performance-based cash bonus paid at 135% of target reflecting strong corporate goal achievement, with base salary representing a reasonable minority of total pay. The company's stock returned +81.3% over three years, outperforming the XBI (SPDR S&P Biotech ETF) by +9.2 percentage points, so above-benchmark incentive pay is justified by shareholder outcomes. The company adopted a Nasdaq-compliant clawback policy in October 2023, and no prior Say on Pay vote result exists to trigger a re-engagement concern.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
4 yrs
Audit Fees
$667,000
Non-Audit Fees
$0
Ernst & Young LLP has audited Mineralys since 2022 (approximately 4 years), well below the 25-year tenure threshold that would raise concerns; non-audit fees are zero, meaning 0% of audit fees go to non-audit work, far below the 50% threshold that would raise independence concerns; and EY is a Big 4 firm fully appropriate for a $2.3 billion market cap company.
Overall Assessment
The 2026 Mineralys Therapeutics annual meeting presents two formal proposals: election of three Class III directors and ratification of Ernst & Young as auditor. All proposals pass policy screens — the director slate is well-qualified with no governance red flags, the stock has meaningfully outperformed the XBI (SPDR S&P Biotech ETF) over three years, and EY's fee structure shows zero non-audit fees and a tenure of only four years.